泽璟制药：获得《药物临床试验批准通知书》

Core Viewpoint - Zai Jian Pharmaceutical has received approval from the National Medical Products Administration for clinical trials of its injectable ZG006 in combination with PD-1/PD-L1 immune checkpoint inhibitors and chemotherapy for small cell lung cancer [1] Group 1: Company Developments - Zai Jian Pharmaceutical's clinical trial for ZG006 has been approved, indicating progress in its oncology pipeline [1] - The company's revenue composition for the year 2024 is projected to be 99.73% from pharmaceutical manufacturing and 0.27% from other businesses [1] Group 2: Market Position - As of the latest report, Zai Jian Pharmaceutical has a market capitalization of 27 billion yuan [2]